четверг, 15 сентября 2011 г.

Symbollon Pharmaceuticals, Inc. Evaluates The Clinical Effects Of IoGen(TM) On Fibrocystic Breast Disease

Iodine has been used as an
antimicrobial for the last century. Much has been written about molecular
iodine yet many women suffering from Fibrocystic Breast Disease (FBD) are
unaware that studies being conducted may soon yield an effective
nonhormonal treatment.



While there are several breast cancer drugs on the market, all
available hormonal therapies have significant adverse events. In contrast,
IoGen is a nonhormonal treatment that allows for safe long-term use with
little or no side effects.



"Current research provides substantive support for the initiation of
human clinical studies on the use of molecular iodine as a treatment for
breast disease," stated Paul Desjourdy, President and CEO, Symbollon
Pharmaceuticals, Inc. "The possibility that IoGen may be used as a
treatment for breast cancer makes it all the more important that we
expedite the commercialization time line."



The Company believes IoGen has the ability to eliminate excess cell
growth in female reproductive tissue, including the breast, ovaries and
uterus. Other indications for IoGen include the treatment or prevention of
endometriosis, ovarian cysts, and premenopausal breast cancer.



Symbollon Pharmaceuticals, Inc. is now in FDA Phase III clinical trials
for the evaluation of IoGen (I2) for pain/tenderness associated with FBD
and with potential to treat female reproductive organ cancers.



The importance of (I2) in the treatments for mammary gland dysfunctions
has been corroborated in human and animal models.



Seaweeds, containing high quantities of iodine in several chemical
forms including (I2), have been associated with low incidences of benign
and malignant breast disease in Asian women.



Past studies by independent researchers have supported the possible
effectiveness of molecular iodine (I2) as a treatment for breast cancer.


-- Researchers at Drexel University College of Medicine found that
molecular iodine alters the gene expression profile in the human breast
cancer cells. Dr. Bernard Eskin remarked that these changes may be
responsible for molecular iodine's inhibition of breast cancer
promotion that has been repeatedly observed in animal models.


-- Some researchers investigating the connection between breast tissue and
iodine observed that frequent childbirth and a long lactation period
are known to reduce the risk of breast cancer.



Symbollon is now conducting its IoGen (I2) Phase III pivotal pain
study. Results are expected in first quarter of 2008. For more information
on IoGen(TM), please visit the company's web site at: symbollon or
mybreastpain.


Symbollon Pharmaceuticals, Inc.

symbollon

четверг, 8 сентября 2011 г.

New Treatments for Common Vaginal Infection, Bacterial Vaginosis, Being Studied

Whether a two-week regimen using a stainless steel douching device can eradicate the most common vaginal infection is
under study at the Medical College of Georgia.


MCG researchers want to know whether the device can eliminate bacterial vaginosis and the distinctive odor that typically
accompanies the infection, says Dr. Daron G. Ferris, family medicine physician, director of the Gynecologic Cancer Prevention
Center at MCG Medical Center and the study's principal investigator.


MCG is the only site in the nation for a two-week test of the device that is based on the same premise as stainless steel
bars chefs use to eliminate undesirable odors from their hands. Participants in a small pilot study who used the device for
one week indicated they were beginning to see improvement, says Dr. Eileen D. Dickman, clinical researcher, coordinator of
the Gynecologic Cancer Prevention Center and a co-investigator.


"Bacterial vaginosis is the most common type of vaginal condition that women experience and yet its etiology is poorly
understood," says Dr. Ferris. "Basically it's an alteration of the vagina's ecosystem. It gets that way because the
lactobacilli, the good bacteria in the vagina, are wiped out."


Good bacteria are critical to the vagina's natural, continuous cleansing process. They secrete lactic acid, which makes the
vagina very acidic, and hydrogen peroxide to kill bad bacteria. Dead cells are carried away in the normally clear discharge.
When the system is disrupted, a woman's natural defense against sexually transmitted diseases decreases, leaving her much
more vulnerable to infections such as HIV, Chlamydia and human papillomavirus. Multiplying bad bacteria produce an
undesirable odor and vaginal discharge may be thick and white.


All sexually active women are at risk for this imbalance; for some unknown reason black women have twice the risk. Regular
vaginal douching may also be a factor, says Dr. Ferris, noting that his counterparts around the world might disagree. "In
America we feel that douching is nonselective: it washes out the good and the bad bacteria," says Dr. Ferris. "After you
douche, if the good bacteria isn't re-established first, the bad bacteria take over and you have a potential problem."
Studies and experience have shown that a major reason women douche is because their mothers did, Dr. Ferris says.


While many European physicians encourage the habit, Dr. Ferris is among the many American physicians who advise their
patients against douching. He wonders if the cylindrical stainless steel device, developed collaboratively by researchers at
Abbott Research Group, Inc. and Carnegie Mellon University in Pittsburgh, may one day be a douching technique he'd recommend.
















Women can easily use the device in the shower. A compartment attached to the device via a tube is filled with body
temperature tap water and placed at an elevated level so the natural force of gravity gently washes out the vagina for a few
minutes.


"I didn't believe this until they sent me a stainless steel chef's bar to try," says Dr. Ferris. "If you get garlic or onion
on your fingers, you use this stainless steel bar to wash your hands without soap, and it gets rid of the odor. Since
bacterial vaginosis is associated with this odor, it's thought the stainless steel has some effect on the whole process and
it could potentially eliminate the infection and the odor as well. This could be a non-pharmacologic, alternative medicine
approach," says Dr. Ferris.


"The standard treatment today is antibiotics to kill the bad bacteria so hopefully the good bacteria can resume dominance.
The goal of the douching device is to clear the infection without antibiotics. We don't know if it will," says Dr. Ferris.
"But, it might be an option other than antibiotics which are not 100 percent effective and can lead to secondary infections,
including yeast."


MCG also is participating in a multi-site study of the first potential new antibiotic for bacterial vaginosis in at least 25
years, a drug called tinidazole, which already has Food and Drug Administration approval to treat trichomoniasis vaginitis,
another common vaginal infection.


Europeans have used tinidazole for years to treat bacterial vaginosis and experience has shown the drug causes less
gastrointestinal side effects than two antibiotics used routinely in the United States. Its efficacy rate may be equivalent
or better than the existing drugs, clindamycin phosphate and metronidazole, Dr. Ferris says.


"We have had the same two antibiotics for a long time so our treatment options are rather limited," says Dr. Ferris, who is
excited about the opportunity to find better treatments for this very common infection with a recurrence rate of about 80
percent.


Women age 18 and older with bacterial vaginosis are eligible for both studies. The douching study is sponsored by Abbott
Research Laboratories and the antibiotic study by Presutti Laboratories.


Contact: Toni Baker

tbakermcg.edu

706-721-4421

Medical College of Georgia

mcg.edu


View drug information on Clindamycin phosphate topical gel.

четверг, 1 сентября 2011 г.

Weak Bladders Deter Many Young Women From Sports Participation

A weak bladder is putting many young women off participating in sport, or prompting them to give it up altogether, suggests research published ahead of print in the British Journal of Sports Medicine.


The prevalence of urinary stress incontinence, defined as an involuntary leakage of urine, is relatively high among women, with some research putting the figure as high as 46%.



The researchers asked 679 Italian women about whether they had ever had urinary stress incontinence. All them were still having regular periods, and took part in non-competitive sports.


The anomymous responses showed that around 1 in 7 (15%) said they suffered from the condition. On average, the women had been putting up with the symptoms for six years.


Being overweight and having had children boosted the risk of urinary stress incontinence.



Of those affected, almost half said the condition occurred during routine activities, while one in three said it occurred solely during sporting activities. One in five said it occurred in both circumstances.


The most risky sports for women with the problem, in descending order of magnitude, were basketball, athletics, and tennis or squash.


Over half of those complaining of the problem experienced up to three episodes of involuntary leakage a month, but for around one in five the frequency of episodes exceeded more than three a week.


One in 10 women said that stress incontinence had prompted them to give up their favourite sport.


A further one in five said that the condition had restricted or forced them to change their activities, in a bid to avoid the risk of leakage.


The figures would have been considerably higher if women who had gone through the menopause had been included in the sample, say the authors.


They conclude that urinary stress incontinence impacts on the quality of women's lives, affecting many aspects of routine and recreational activities, but few women seek help for the condition, they say.


"They should be given information and offered diagnostic and conservative therapeutic options," including pelvic floor exercises, which can be very helpful, they add.


"The impact of urinary stress incontinence in young and middle aged women practising recreational sports activity: an epidemiological study."

Online First Br J Sports Med 10.1136/bjsm.2008.049072

bjsm.bmj

British Journal of Sports Medicine

четверг, 25 августа 2011 г.

Lipstick Contains Detectable Levels Of Lead Says Campaign Group Report

A report released yesterday by the Campaign for Safe Cosmetics (CSC), a coalition of women's, public health, and environmental groups campaigning for
the phasing out of toxins in cosmetics, has suggested that over half of 33 top brands of lipsticks on sale in the US contain detectable levels of
lead.


The report said that tests conducted by an independent laboratory during September this year found that 61 per cent of 33 brand-name red lipsticks contained
detectable levels of lead ranging from 0.03 to 0.65 parts per million (ppm). The lipsticks were bought in Boston, Hartford, Connecticut, San Francisco and
Minneapolis.


One third of the lipsticks tested by the laboratory were found to contain more than the 0.1 ppm limit imposed by the US Food and Drug Administration on candy
and sweets. Although the limit for candy was set to protect children from ingesting lead, the CSC is using this comparison to show that lipstick, which is
put directly onto the lips, is also a source of directly ingested lead, to which pregnant women for example are particularly vulnerable. But the CSC pointed
out that the FDA has not set a limit for lead in lipstick.


The CSC report said 39 per cent of the lipsticks tested had no detectable levels of lead, suggesting it was possible to make them without lead. However,
cost does not seem to be a factor, they said, since cheaper brands such as Revlon, selling at 7.49 dollars an item had no detectable levels of lead but the
most expensive lipstick they tested, the Dior Addict brand, selling at 24 dollars 50 an item had higher levels than some of the other lipsticks.


The CSC said that the top brands that tested positive for lead in their red lipsticks included:

L'Oreal Colour Riche "True Red" (lead level of 0.65 ppm),
L'Oreal Colour Riche "Classic Wine" (0.58 ppm),
Cover Girl Incredifull Lipcolor "Maximum Red" (0.56 ppm), and
Dior Addict "Positive Red" (0.21 ppm).

Referring to studies that said there is no safe level for lead, and that it is a toxin that builds up in the human body because we can't excrete it, Dr Mark
Mitchell, president of the Connecticut Coalition for Environmental Justice, said:


"Lead-containing lipstick applied several times a day, every day, can add up to significant exposure levels."


Stacy Malkan, author of the new book, "Not Just a Pretty Face: The Ugly Side of the Beauty Industry", also referred to the build up of toxins like lead in
the body, and said the cosmetics industry needs to "clean up its act" and take immediate steps to reformulate products that contain lead.


John Bailey, EVP for Science Cosmetic, Toiletry, and Fragrance Association, said yesterday in a statement responding to the CSC report that despite repeated
allegations to the contrary over the years, the cosmetics industry does not add lead to its products; the metal occurs naturally in a range of ingredients, as
it does "everywhere in the environment".















He said consumers were exposed to lead every day when they "eat, drink water, and breathe the air".


Bailey pointed out that the average quantity of lead a woman would be exposed to from using cosmetics amounted to 1,000th of the amount she would ingest from
eating food, breathing in air and drinking water that met the drinking water standards set by the Environmental Protection Agency (EPA).


Referring to the FDA, Bailey said the agency set daily safe levels of lead exposure for adults, children and women who were expecting. And, implying a
contradiction to the CSC report, he said the FDA also set limits for lead in the colours used in lipsticks, and also tests them to make sure the limits are
obeyed. In fact he also said that the "products identified in the Campaign for Safe Cosmetics (CSC) report meet these standards."


Bailey said that for decades the cosmetics industry has worked to "minimize all product contamination, including lead", and they employed some of the world's
leading scientists to do this.


The Houston Chronicle reported yesterday that the FDA had no plans to act in response to the CSC report and the agency has been aware of concerns about lead
in lipstick for some time.


A pediatrician and assistant professor at Baylor College of Medicine, Dr Sara Rizvi, who was contacted by the Chronicle said the report's findings were
"troubling". However, she said there was no cause for panic since the report was inconclusive and even showed different levels of lead in the same
brand.


But Rizvi also went on to say that although more research was needed to establish conclusive evidence one way or the other, the industry should reformulate
products to remove lead completely, since this was an avoidable risk.


In high doses lead has been linked to learning and behavioural problems in children, such as reduced IQ, poorer school performance and aggression, said the
CSC. The unborn and the very young are especially vulnerable because lead affects early brain development.


Click here for the CSC report on lead in lipstick.


Click here to learn more about lead exposure and toxicity from the US Centers for Disease Control and
Prevention (CDC).


: Catharine Paddock




четверг, 18 августа 2011 г.

University of Michigan Study Finds Women Underrepresented In Cancer Research

Women are under-represented in clinical cancer research published in high-impact journals, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center.



Taking into account the incidence of particular types of cancer among women, studies included a smaller proportion of women than should be expected. The analysis looked specifically at studies of cancer types that were not gender specific, including colon cancer, oral cancers, lung cancer, brain tumors and lymphomas.



The authors looked at 661 prospective clinical studies with more than 1 million total participants. Results of this study appear online in the journal Cancer and will be published in the July 15 print issue.



"In the vast majority of individual studies we analyzed, fewer women were enrolled than we would expect given the proportion of women diagnosed with the type of cancer being studied. We're seeing it across the board in all cancer types," says study author Reshma Jagsi, M.D., D.Phil., assistant professor of radiation oncology at the U-M Medical School.



"It's so important that women are appropriately represented in research. We know there are biological differences between the sexes, as well as social and cultural differences. Studies need to be able to assess whether there are differences in responses to treatment, for example, between women and men," she adds.



The National Institutes of Health's Revitalization Act of 1993 explicitly calls out the importance of including women in clinical research, noting that clinical trials should enroll adequate numbers of women to allow for subgroup analysis.



The U-M researchers found that studies reporting government funding did include higher numbers of women participants, but the impact was modest - 41 percent, compared to 37 percent for studies not receiving government funding.



Traditionally, researchers were told not to include people of vulnerable populations in their studies. This group included women of childbearing age. "By protecting them from research, we're excluding them," Jagsi notes.



Previous studies have found some barriers to clinical trial participation are lack of information, fear and a perception of interfering with personal responsibilities, such as child care.



"Sometimes participating in research studies can be time intensive. Women today are often stretched very thin trying to deal with the balance between domestic responsibilities, their cancer diagnosis, and often a career as well. They may be particularly likely to find clinical trials too burdensome. In that case, researchers should consider providing compensation to help with transportation or child care expenses," Jagsi says.



This under-representation of women is not necessarily the result of conscious decisions, points out senior author Peter Ubel, M.D., director of the Center for Behavioral and Decision Sciences in Medicine at U-M.



"Clinical researchers are not purposely trying to exclude women from their studies. All the more reason they need to consciously and earnestly revise their recruitment methods to give more women a chance to volunteer," Ubel says.



Notes:

Methodology: The researchers looked at all original clinical cancer research published in five top oncology journals and three top general medical journals in 2006. The journals included were the New England Journal of Medicine, the Journal of the American Medical Association, the Lancet, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, Lancet Oncology, Clinical Cancer Research and Cancer. Articles were analyzed to determine factors including the number of participants, gender of participants, type of cancer and funding source. The percent of women was summarized in two ways: The overall percent of women from all studies; and the average percent from each study that were women. The first method gives greater weight to larger studies, while the second method allows each study to have equal weight. Women's representation was lower than expected, based on general population incidence data, according to both analyses. Additional authors: Amy R. Motomura, Sudha Amarnath, Aleksandra Jankovic, M.S., Nathan Sheets, Peter A. Ubel, M.D. Funding: University of Michigan Institute for Research on Women and Gender.



Source:
Nicole Fawcett


University of Michigan Health System

четверг, 11 августа 2011 г.

High Insulin Levels Raise Risk Of Breast Cancer In Postmenopausal Women

Higher-than-normal levels of insulin place postmenopausal women at increased risk of breast cancer, researchers at Albert Einstein College of Medicine of Yeshiva University report. Their findings, published in the January 7 issue of the Journal of the National Cancer Institute, suggest that interventions that target insulin and its signaling pathways may decrease breast cancer risk in these women.


Breast cancer is the most common cancer among women in the United States. Last year, approximately 182,000 women were diagnosed with breast cancer and more than 40,000 died from the disease. The majority of breast cancers arise in women past the age of menopause.


Obesity is a well established risk factor for postmenopausal breast cancer, but just how obesity and breast cancer are connected is unclear. Many researchers have assumed that the link is estrogen a hormone that is known to increase breast-cancer risk and is found at higher-than-average levels in obese women. But obese women also have other hormonal imbalances that may play a role in triggering breast cancer. One such imbalance is elevated levels of insulin, which stimulates the growth of breast cells in tissue culture. The Einstein study is the first to prospectively identify insulin's role in breast cancer while controlling for estrogen levels.


The multi-year Women's Health Initiative (WHI) the largest study of postmenopausal women ever funded by the National Institutes of Health followed health outcomes in more than 93,000 postmenopausal women. At enrollment, each participant donated blood samples that were stored for later analysis.


In 2004, the Einstein researchers selected a subset of more than 1,600 of these participants: 835 who had developed breast cancer during the study, and a random sample of 816 women representative of the WHI as a whole. Using the blood samples and other measurements taken when the women enrolled, the researchers assessed their fasting insulin level, naturally occurring levels of estradiol (a form of estrogen), and body mass index, or BMI (a measure of obesity). After dividing the women into four groups based on their fasting insulin levels and controlling for estrogen levels, the researchers found that women with the highest insulin levels were nearly 50 percent more likely to have developed breast cancer compared with women who had the lowest insulin levels.


Most of this effect was observed in the large subset of women from the WHI study who did not use hormone-replacement therapy. HRT has a strong effect on insulin and other hormonal factors, so eliminating this variable gives a clearer picture of insulin's effect on breast cancer. "Among these women, the influence of insulin on breast cancer risk was quite high," says lead author Marc Gunter, Ph.D., assistant professor of epidemiology & population health at Einstein. "Women with the highest insulin levels in their blood were more than two times more likely to develop breast cancer than women with the lowest insulin levels." Moreover, "when we controlled for insulin, the association between obesity and breast cancer became much weaker," adds Dr. Gunter. "This means that a large component of that obesity-cancer relationship may be mediated by insulin levels."















The findings have important implications for prevention, and possibly treatment, of postmenopausal breast cancer, according to Howard Strickler, M.D., M.P.H, who was senior author of the paper and a professor of epidemiology & population health at Einstein. "Research now needs to focus on ways to reduce insulin's effects on cell growth and replication in the breast while preserving its positive metabolic effects.


There are several possibilities and working with our laboratory collaborators we hope to make fast progress," said Dr. Strickler.


"It is also possible that screening non-diabetic postmenopausal women for high insulin levels could prove useful in identifying individuals at high risk for breast cancer," says Dr. Strickler.


The current study is part of a broader research program at Einstein. Researchers are focusing on how the effects of insulin and insulin-like growth factors on cell replication and survival influence a variety of conditions. "Every cell in the body carries insulin receptors and most carry IGF-1 receptors, so it makes sense that this biologic pathway could play a major role in health and disease across a broad range of conditions and we have to do much more to understand these relationships," notes Dr. Strickler. So far, studies by Dr. Strickler and his colleagues have shown that insulin and/or IGFs also play a role in endometrial and colorectal cancer, as well as the progression of certain viral diseases, including HIV, hepatitis C virus in the liver and human papillomavirus (the cause of cervical cancer).


About Albert Einstein College of Medicine of Yeshiva University


Albert Einstein College of Medicine of Yeshiva University is one of the nation's premier centers for research, medical education and clinical investigation. It is the home to some 2,000 faculty members, 750 M.D. students, 350 Ph.D. students (including 125 in combined M.D./Ph.D. programs) and 380 postdoctoral investigators. Last year, Einstein received more than $130 million in support from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Through its extensive affiliation network involving five hospital centers in the Bronx, Manhattan and Long Island which includes Montefiore Medical Center, Einstein's officially designated University Hospital the College runs one of the largest post-graduate medical training program in the United States, offering approximately 150 residency programs to more than 2,500 physicians in training. For more information, please visit aecom.yu.edu.


Albert Einstein College of Medicine of Yeshiva University

1300 Morris Park Ave.

Bronx

NY 10461

United States

aecom.yu.edu



View drug information on Estradiol Transdermal System.

четверг, 4 августа 2011 г.

At ASPS Annual Meeting: Innovative 'No Breast Implant' Procedure

Women who desire a mommy-makeover, have had major weight loss, or are unhappy with the toll age has taken on their breasts can breathe easier. An innovative procedure to correct severely deflated, sagging breasts left looking like "pancakes" will be presented at the American Society of Plastic Surgeons (ASPS) Plastic Surgery 2008 conference, Oct. 31 - Nov. 5, in Chicago. The procedure corrects misshapen breasts by lifting and restoring them to a more natural, full shape and position without the use of breast implants.



"In the past several years I've seen more women in their 50s who are unhappy with their breasts," said Dennis Hurwitz, MD, ASPS Member Surgeon and course instructor. "These women have had numerous pregnancies, waited later in life to have children, lost a lot of weight, or simply haven't aged well and want to restore their figure. The breast irregularities these patients share are unique. These are extreme cases - not your 'run of the mill' augmentation patients who simply want to enlarge their breasts from an A to C cup."



The procedure presented at Plastic Surgery 2008 uses unwanted tissue and fat from the patient's tummy, along the bra line, or beneath the upper arm, shapes it into a breast mound and secures it with absorbable sutures into a tissue sheet that acts like a sling to hold the flap into position. This "spiral flap" is mobile enough to permit artistry in shaping, positioning and enlarging the breast. According to Dr. Hurwitz, the breasts are not only enlarged and better-shaped; they are soft and shift naturally with changes in body position. Patients also get the dual benefit of body contouring.



Currently, the majority of these patients are treated with conventional breast surgery, generally with less patient satisfaction. However, the "spiral flap" technique should not be substituted for standard breast implant augmentation, augmentation with breast lift, or breast reduction in all patients. While the procedure may be an option for a small percentage of women (post-pregnancy or as a result of aging) with extremely flattened chests who have ample excess skin around their mid torso, the majority treated with this technique are massive weight loss patients.



"For these women, so much volume and skin elasticity is gone that a basic breast augmentation or lift just doesn't produce optimal results," said Dr. Hurwitz. "By using the patients own tissue, they get a more natural augmentation with the dual benefit of body contouring."







Nearly 348,000 breast augmentations were performed in 2007, making it the number one cosmetic plastic surgery procedure last year, according to ASPS statistics. In addition, more than 106,000 breast reductions and 104,000 breast lifts were performed last year.



The American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world. Representing more than 6,700 physician members, the Society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS comprises more than 90 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada.



Source:ASPS Public Relations


American Society of Plastic Surgeons